SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-166563
Filing Date
2017-05-11
Accepted
2017-05-11 07:01:21
Documents
45
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d349103d10q.htm 10-Q 225967
2 EX-31.1 d349103dex311.htm EX-31.1 6003
3 EX-32.1 d349103dex321.htm EX-32.1 3210
  Complete submission text file 0001193125-17-166563.txt   1827776

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT rxii-20170331.xml EX-101.INS 288754
5 XBRL TAXONOMY EXTENSION SCHEMA rxii-20170331.xsd EX-101.SCH 23892
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rxii-20170331_cal.xml EX-101.CAL 34166
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rxii-20170331_def.xml EX-101.DEF 95379
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxii-20170331_lab.xml EX-101.LAB 204922
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxii-20170331_pre.xml EX-101.PRE 148779
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 17832491
SIC: 2834 Pharmaceutical Preparations